ReviewThe American journal of medicine2019
Heart Failure With Preserved Ejection Fraction: Is Ischemia Due to Coronary Microvascular Dysfunction a Mechanistic Factor?
Review in The American journal of medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Hypoxia-mediated epicardial signaling coordinates coronary angiogenesis and myocardial expansion during zebrafish ventricle maturation.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Sex-specific traditional and disease-related risk factors for incident heart failure in patients with rheumatoid arthritis: a registry-based cohort study.Clinical rheumatology · 2026Article
- Incorporating angina into the HOpen heart · 2026Article
- Underpinnings of heart failure with preserved ejection fraction in women - From prevention to improving function. A co-publication with the American Journal of Preventive Cardiology and the Journal of Cardiac Failure.American journal of preventive cardiology · 2025Article
- Prognostic value of the HFA-PEFF and H(2) FPEF scores for clinical outcomes in patients with coronary artery disease and preserved ejection fraction.International journal of cardiology. Heart & vasculature · 2025Article
- Multimodality Imaging in the Diagnosis of Coronary Microvascular Disease: An Update.Journal of personalized medicine · 2025Review
- Shexiang Tongxin Dropping Pill Promotes Angiogenesis through VEGF/eNOS Signaling Pathway on Diabetic Coronary Microcirculation Dysfunction.Chinese journal of integrative medicine · 2024Article
- Clinical Update in Heart Failure with Preserved Ejection Fraction.Current heart failure reports · 2024Review
- Cardiac MRI in heart failure with preserved ejection fraction.La Radiologia medica · 2024Review
- Role of Circulating Biomarkers in Diabetic Cardiomyopathy.Biomedicines · 2024Review
- Navigating the Landscape of Coronary Microvascular Research: Trends, Triumphs, and Challenges Ahead.Reviews in cardiovascular medicine · 2024Review
- Non-coding RNAs as therapeutic targets and biomarkers in ischaemic heart disease.Nature reviews. Cardiology · 2024Review
- Imaging Early Life Cardiovascular Phenotype.Circulation research · 2023Review
- Obesity, Preserved Ejection Fraction Heart Failure, and Left Ventricular Remodeling.Journal of clinical medicine · 2023Review
- Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies:JACC. CardioOncology · 2023Review
- Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?International journal of molecular sciences · 2022Review
- Prognostic significance of obstructive coronary artery disease in patients admitted with acute decompensated heart failure: the ARIC study community surveillance.European journal of heart failure · 2022Article
- Imaging techniques for the assessment of adverse cardiac remodeling in metabolic syndrome.Heart failure reviews · 2022Review
- Non-obstructive Plaque and Treatment of INOCA: More to Be Learned.Current atherosclerosis reports · 2022Review
- Novel biomarkers of inflammation in heart failure with preserved ejection fraction: analysis from a large prospective cohort study.BMC cardiovascular disorders · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Heart failure with preserved ejection fraction (HFpEF) is increasing in prevalence and has no guideline-recommended therapy, related in part to a lack of mechanism. Traditionally, HFpEF was thought to be secondary to afterload overload due to systemic hypertension; however, accumulating evidence suggests that HFpEF continues to worsen despite adequate control of blood pressure. Emerging data support the suggestion that myocardial ischemia secondary to coronary microvascular dysfunction could be the new paradigm pathophysiology. Several prospective, observational cohort studies indicate that the outcomes of patients with microvascular dysfunction, after an interval of several years, are dominated by HFpEF hospitalizations. Further, the most prevalent clinical phenotype (eg older women with multiple comorbidities) of patients with HFpEF resembles those with coronary microvascular dysfunction, albeit older. In this review, we provide in-depth insight about this emerging HFpEF paradigm, discuss potential therapeutic implications of this pathophysiology, and summarize some important knowledge gaps.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.